J. Ward

发表

Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies

N. Wood, S. Haughie, R. Allan, 2020, Journal of aerosol medicine and pulmonary drug delivery.

Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler

M. Silverman, S. Haughie, D. Hava, 2019, British journal of clinical pharmacology.

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD

J. Vestbo, J. Ward, G. Atkinson, 2009, European Respiratory Journal.

Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD

J. Donohue, R. Allan, J. Ward, 2020, Pulmonary Therapy.

A Dose-Response Study Examining the Use of Methacholine Challenge to Demonstrate Local Therapeutic Equivalence of the Salmeterol Component of Generic Inhaled Fluticasone Propionate/Salmeterol Combination Products.

R. Ahrens, S. Haughie, Sachinkumar Singh, 2019, Journal of aerosol medicine and pulmonary drug delivery.

A Dose-Response Study to Examine the Methodology for Demonstrating the Local Therapeutic Equivalence of the Fluticasone Propionate Component of an Orally Inhaled Combination Therapy of Fluticasone Propionate/Salmeterol Dry Powder.

E. Kerwin, S. Haughie, R. Allan, 2019, Journal of aerosol medicine and pulmonary drug delivery.

A controlled trial of 6 weeks’ treatment with a novel inhaled PDE4 inhibitor in COPD

J. Vestbo, J. Ward, G. Atkinson, 2009 .

Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease

J. Backer, G. Crater, J. Ward, 2022, Therapeutic advances in respiratory disease.

Wixela Inhub: Dosing Performance In Vitro and Inhaled Flow Rates in Healthy Subjects and Patients Compared with Advair Diskus

R. Wallace, R. Allan, J. Ward, 2020, Journal of aerosol medicine and pulmonary drug delivery.

The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device

D. Tashkin, J. Ohar, R. Allan, 2021, Pulmonary medicine.

Usability and Robustness of the Wixela Inhub Dry Powder Inhaler

Dave Singh, K. Canham, R. Wallace, 2020, Journal of aerosol medicine and pulmonary drug delivery.

Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma

E. Kerwin, S. Miller, M. White, 2020, Journal of aerosol medicine and pulmonary drug delivery.

Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD

N. Hanania, S. Sethi, J. Ward, 2018, International journal of chronic obstructive pulmonary disease.

The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients.

J. Lötvall, M. Palmqvist, J. Ward, 2001, The Journal of allergy and clinical immunology.